 Christopher Striebich
Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 13 | 2023 | 1003 | 1.130 |
Why?
| | Susac Syndrome | 1 | 2011 | 3 | 0.370 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 64 | 0.360 |
Why?
| | Antirheumatic Agents | 2 | 2023 | 255 | 0.290 |
Why?
| | Interferon-alpha | 2 | 2021 | 186 | 0.280 |
Why?
| | Rheumatoid Factor | 4 | 2022 | 157 | 0.280 |
Why?
| | Autoantibodies | 6 | 2023 | 1349 | 0.270 |
Why?
| | Endothelium, Vascular | 1 | 2011 | 847 | 0.240 |
Why?
| | Meniscus | 1 | 2023 | 21 | 0.210 |
Why?
| | Rheumatology | 1 | 2023 | 88 | 0.200 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 382 | 0.200 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2023 | 130 | 0.190 |
Why?
| | STAT1 Transcription Factor | 1 | 2021 | 64 | 0.180 |
Why?
| | Anti-Citrullinated Protein Antibodies | 2 | 2020 | 90 | 0.180 |
Why?
| | Lovastatin | 1 | 2020 | 26 | 0.180 |
Why?
| | Osteoarthritis, Knee | 1 | 2023 | 213 | 0.170 |
Why?
| | Methotrexate | 2 | 2021 | 226 | 0.170 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2023 | 246 | 0.160 |
Why?
| | STAT3 Transcription Factor | 1 | 2021 | 173 | 0.160 |
Why?
| | Interleukin-10 | 1 | 2021 | 299 | 0.160 |
Why?
| | Synovial Fluid | 1 | 1998 | 56 | 0.160 |
Why?
| | Rheumatic Diseases | 1 | 2019 | 49 | 0.160 |
Why?
| | C-Reactive Protein | 1 | 2020 | 362 | 0.150 |
Why?
| | B-Lymphocytes | 3 | 2012 | 766 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 1998 | 309 | 0.140 |
Why?
| | Triage | 1 | 2019 | 199 | 0.140 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2017 | 122 | 0.130 |
Why?
| | Autoimmunity | 2 | 2012 | 813 | 0.130 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 373 | 0.130 |
Why?
| | Interferon-beta | 1 | 2015 | 79 | 0.120 |
Why?
| | Epitopes | 3 | 2023 | 435 | 0.120 |
Why?
| | Wrist Injuries | 1 | 2014 | 25 | 0.120 |
Why?
| | Ligaments, Articular | 1 | 2014 | 55 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2011 | 82 | 0.110 |
Why?
| | Stress, Psychological | 1 | 2020 | 944 | 0.100 |
Why?
| | Rituximab | 2 | 2011 | 150 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1998 | 959 | 0.100 |
Why?
| | Range of Motion, Articular | 1 | 2014 | 350 | 0.100 |
Why?
| | Muscle Strength | 1 | 2014 | 271 | 0.100 |
Why?
| | Bronchial Diseases | 1 | 2011 | 38 | 0.100 |
Why?
| | Labor, Induced | 1 | 2011 | 32 | 0.090 |
Why?
| | Recovery of Function | 1 | 2014 | 574 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2015 | 1140 | 0.090 |
Why?
| | Cyclophosphamide | 1 | 2011 | 217 | 0.090 |
Why?
| | Immune Tolerance | 1 | 2012 | 323 | 0.090 |
Why?
| | Genes, Immunoglobulin | 1 | 1990 | 26 | 0.090 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2011 | 122 | 0.090 |
Why?
| | Signal Transduction | 2 | 2021 | 4516 | 0.080 |
Why?
| | Health Fairs | 1 | 2009 | 9 | 0.080 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 1990 | 72 | 0.080 |
Why?
| | Synovitis | 1 | 2009 | 24 | 0.080 |
Why?
| | Treatment Outcome | 5 | 2020 | 9088 | 0.080 |
Why?
| | Humans | 18 | 2023 | 114709 | 0.080 |
Why?
| | Middle Aged | 10 | 2021 | 26738 | 0.080 |
Why?
| | Aspirin | 1 | 2011 | 324 | 0.080 |
Why?
| | Female | 12 | 2022 | 59523 | 0.080 |
Why?
| | Adult | 8 | 2021 | 30554 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 951 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 497 | 0.070 |
Why?
| | Immunoglobulin M | 2 | 2022 | 246 | 0.070 |
Why?
| | Biomarkers | 4 | 2021 | 3408 | 0.070 |
Why?
| | Male | 11 | 2022 | 55609 | 0.060 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2008 | 219 | 0.060 |
Why?
| | Lung Diseases | 1 | 2011 | 701 | 0.060 |
Why?
| | Rheumatologists | 1 | 2023 | 12 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 646 | 0.060 |
Why?
| | Risk Factors | 3 | 2023 | 8634 | 0.050 |
Why?
| | Incidence | 2 | 2020 | 2313 | 0.050 |
Why?
| | Phosphorylation | 2 | 2021 | 1569 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2021 | 2540 | 0.050 |
Why?
| | Colorado | 3 | 2020 | 4100 | 0.050 |
Why?
| | Mass Screening | 1 | 2009 | 1006 | 0.050 |
Why?
| | Prospective Studies | 3 | 2022 | 6220 | 0.050 |
Why?
| | Peptides, Cyclic | 2 | 2017 | 253 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 32 | 0.050 |
Why?
| | Aged | 5 | 2021 | 19074 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 1264 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 2022 | 166 | 0.050 |
Why?
| | Abatacept | 1 | 2021 | 40 | 0.050 |
Why?
| | Complement Activation | 1 | 2023 | 340 | 0.040 |
Why?
| | Joints | 2 | 2011 | 84 | 0.040 |
Why?
| | Pregnancy | 1 | 2011 | 5520 | 0.040 |
Why?
| | Sequence Analysis | 1 | 1998 | 35 | 0.040 |
Why?
| | Clone Cells | 1 | 1998 | 247 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2021 | 493 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2021 | 6347 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2020 | 1660 | 0.030 |
Why?
| | Patient Selection | 1 | 2019 | 641 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 953 | 0.030 |
Why?
| | Base Sequence | 1 | 1998 | 2114 | 0.030 |
Why?
| | Lunate Bone | 1 | 2014 | 9 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1075 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 1998 | 1982 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1211 | 0.030 |
Why?
| | Scaphoid Bone | 1 | 2014 | 19 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2387 | 0.030 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2785 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2021 | 3004 | 0.030 |
Why?
| | Young Adult | 3 | 2015 | 10472 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 4410 | 0.030 |
Why?
| | Syk Kinase | 1 | 2012 | 18 | 0.030 |
Why?
| | Immunoglobulin D | 1 | 2012 | 27 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2012 | 20 | 0.030 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2012 | 27 | 0.030 |
Why?
| | Clonal Anergy | 1 | 2012 | 53 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2022 | 12556 | 0.030 |
Why?
| | Antigens, CD19 | 1 | 2012 | 91 | 0.020 |
Why?
| | Arthrography | 1 | 2011 | 22 | 0.020 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2012 | 107 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 2968 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1998 | 1701 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1694 | 0.020 |
Why?
| | Databases, Factual | 1 | 2015 | 1125 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1796 | 0.020 |
Why?
| | Blotting, Northern | 1 | 1990 | 193 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 388 | 0.020 |
Why?
| | Cross Reactions | 1 | 1990 | 117 | 0.020 |
Why?
| | Immunoglobulin Variable Region | 1 | 1990 | 72 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 367 | 0.020 |
Why?
| | Hybridomas | 1 | 1990 | 230 | 0.020 |
Why?
| | Antibody Specificity | 1 | 1990 | 176 | 0.020 |
Why?
| | Autoantigens | 1 | 2012 | 396 | 0.020 |
Why?
| | Molecular Weight | 1 | 1990 | 331 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 1990 | 271 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2009 | 138 | 0.020 |
Why?
| | Multigene Family | 1 | 1990 | 190 | 0.020 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 89 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2012 | 395 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4411 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 1990 | 502 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 217 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2008 | 27 | 0.020 |
Why?
| | Registries | 1 | 2015 | 1768 | 0.020 |
Why?
| | Prognosis | 1 | 2015 | 3330 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 133 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2008 | 116 | 0.020 |
Why?
| | United States | 1 | 2022 | 12186 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2286 | 0.020 |
Why?
| | Gene Expression | 1 | 1990 | 1421 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 2765 | 0.010 |
Why?
| | Inflammation | 1 | 2011 | 2480 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 4624 | 0.010 |
Why?
| | Adolescent | 1 | 2014 | 17855 | 0.010 |
Why?
| | Mice | 1 | 1990 | 14872 | 0.010 |
Why?
| | Animals | 1 | 1990 | 31709 | 0.000 |
Why?
|
|
Striebich's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|